v3.26.1
Reverse Recapitalization and Sonnet Acquisition - Summary of Cost of Acquisition and Allocation to Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 11, 2025
Mar. 31, 2026
Cost of the Acquisition    
Fair value of common stock issued   $ 1,470
Common Stock [Member]    
Cost of the Acquisition    
Fair value of common stock issued   $ 3
Sonnet BioTherapeutics Holdings, Inc. [Member]    
Assets Acquired and Liabilities Assumed    
Cash $ 10,347  
Assembled workforce 800  
In-process research and development 35,605  
Other assets 1,788  
Accounts payable (2,707)  
Accrued expenses and other current liabilities (999)  
Total net assets acquired 44,834  
Cost of the Acquisition    
Fair value of common stock issued 17,800  
Total consideration paid to Sonnet 35,510  
Transaction costs 9,324  
Total cost of the acquisition 44,834  
Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]    
Cost of the Acquisition    
Fair value of common stock issued 17,771  
Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member]    
Cost of the Acquisition    
Fair value of common stock issued 12,478  
Cash to settle outstanding Sonnet warrants $ 5,261